Bio-Techne posted a 4 percent revenue increase in Q4 fiscal 2025 to $317 million, driven by strong demand in protein sciences and cell therapy workflow solutions despite a 1 percent decline in diagnostics and spatial biology revenues. The diagnostics segment faced headwinds from constrained NIH funding and softer biotech investment climates, impacting academic customer demand and delaying instrument placements. The company plans to divest its Exosome Diagnostics business. Leadership highlighted ongoing uncertainties related to NIH budgets and potential pharmaceutical tariffs but remain optimistic about continued momentum in the biopharmaceutical market.